Welcome to our dedicated page for Heron Therapeutics SEC filings (Ticker: HRTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Heron Therapeutics, Inc. (HRTX) SEC filings page provides access to the company’s official regulatory documents as filed with the U.S. Securities and Exchange Commission. As a Nasdaq‑listed commercial-stage biotechnology company, Heron uses Forms 10‑K, 10‑Q, 8‑K, and proxy statements on Schedule 14A to report financial results, material events, and governance matters related to its acute care and oncology supportive care business.
Investors reviewing HRTX SEC filings can examine current reports on Form 8‑K that disclose items such as quarterly and year‑to‑date financial results, capital restructuring transactions, amendments to credit facilities with Hercules Capital, Inc., exchange and issuance of convertible senior unsecured promissory notes, private placements of common and preferred equity, and adoption of a Tax Benefit Preservation Plan intended to protect net operating loss carryforwards. Other 8‑K filings describe material agreements, manufacturing and supply arrangements with Patheon, office lease commitments for corporate headquarters, and changes in the composition of the Board of Directors.
Heron’s proxy statements on Schedule 14A provide detail on stockholder meetings, including special meetings to approve the issuance of common stock upon conversion of convertible notes and Series A Convertible Preferred Stock under Nasdaq Listing Rule 5635(d). These documents explain voting procedures, virtual meeting logistics, and the specific proposals presented to stockholders.
Through this page, users can also track governance and capital structure disclosures such as the creation of Series A Convertible Preferred Stock and Series B Preferred Stock, rights plans, and cooperation agreements with significant investors. Stock Titan enhances these filings with AI‑powered summaries that highlight key terms, financial implications, and governance changes, helping readers quickly understand complex agreements without replacing the full legal text. Real‑time updates from EDGAR ensure that new HRTX filings, including 10‑K annual reports, 10‑Q quarterly reports, and Form 4 insider transaction reports when available, are surfaced promptly for further analysis.
Heron Therapeutics executive William P. Forbes reported a routine equity vesting transaction. On 01/19/2026, 3,875 restricted stock units converted into an equal number of shares of Heron Therapeutics common stock, at an exercise price of $0.00 per unit. Following this conversion, Forbes directly held 30,994 restricted stock units and 170,078 shares of common stock. The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the original grant date of 01/19/2024, reflecting ongoing equity-based compensation rather than an open-market share sale.
Heron Therapeutics EVP and Chief Financial Officer Ira Duarte reported the vesting of restricted stock units and corresponding acquisition of common stock. On 01/19/2026, 3,875 restricted stock units were converted into 3,875 shares of common stock at a price of $0 per share in a transaction coded "M," which indicates an exercise or conversion. Following this transaction, Duarte directly held 183,661 shares of Heron Therapeutics common stock and 30,994 restricted stock units.
The footnotes explain that each restricted stock unit represents a right to receive one share of common stock and that the units vest in 16 equal quarterly installments starting one quarter after the grant date of 01/19/2024. This reflects routine equity compensation vesting for a senior executive rather than an open-market purchase or sale.
Heron Therapeutics, Inc. Chief Executive Officer Craig A. Collard reported an RSU vesting and share acquisition on 01/19/2026. A total of 13,797 restricted stock units were converted at an exercise price of $0 into 13,797 shares of common stock, reflecting previously granted equity compensation rather than an open-market purchase.
Each restricted stock unit represents a contingent right to receive one share of common stock, and these RSUs vest in 16 equal quarterly installments beginning one quarter after the 01/19/2024 grant date. Following this transaction, Collard directly held 110,375 restricted stock units and 536,921 shares of common stock.
Heron Therapeutics, Inc. filed a current report to share that it has issued a press release with preliminary financial results for the three months ended December 31, 2025 and for full-year 2025. The company furnished this press release as Exhibit 99.1 under a Regulation FD disclosure item, meaning it is being provided for informational purposes and is not treated as formally filed for liability purposes under Section 18 of the Exchange Act. The company also notes that this information will only be incorporated into other securities filings if specifically referenced.
Heron Therapeutics (HRTX) reported a director equity grant. On 11/08/2025, the reporting person acquired 37,879 shares of common stock via restricted stock units, with 37,879 shares beneficially owned following the transaction. Each RSU equals one share and vests in 16 equal quarterly installments beginning one quarter after grant.
On the same date, the director received stock options for 227,272 shares at an exercise price of $1.1, expiring on 11/08/2035. These options vest in 48 equal monthly installments starting one month after grant.
Heron Therapeutics (HRTX) reported an initial statement of beneficial ownership on Form 3 for director Thomas P. Cusack. The filing states that, as of the event date 10/27/2025, no securities are beneficially owned.
The report indicates it was filed by one reporting person and lists no non-derivative or derivative holdings, with the explanation: “No securities are beneficially owned.” The signature is provided by an attorney-in-fact on behalf of the reporting person.
Heron Therapeutics (HRTX): Officer William P. Forbes reported an RSU vesting and settlement. On 10/31/2025, 11,694 shares of common stock were acquired from restricted stock units at a price of $0.00 per share (Transaction Code M). Following this, he beneficially owned 166,203 shares directly. The filing also lists 152,027 restricted stock units remaining after the transaction.
Each restricted stock unit represents the right to receive one share of common stock. The RSUs vest in 16 equal installments beginning one quarter after the grant date, January 31, 2025.
Heron Therapeutics (HRTX) reported an insider transaction by EVP & Chief Financial Officer Ira Duarte. On 10/31/2025, 11,694 shares of common stock were acquired upon settlement of restricted stock units. After this transaction, 179,786 common shares are beneficially owned directly, and 152,027 restricted stock units remain outstanding. The RSUs vest in 16 equal installments beginning one quarter after the grant date of January 31, 2025.
Heron Therapeutics (HRTX) reported an insider transaction: CEO and Director Craig Collard acquired 34,789 shares of common stock on 10/31/2025 through settlement of restricted stock units (transaction code M) at $0.
Following the transaction, Collard directly owned 523,124 shares. He also beneficially owned 452,253 RSUs after the event. The RSUs vest in 16 equal installments beginning one quarter after the grant date of January 31, 2025.
Heron Therapeutics (HRTX) reported Q3 2025 results with net product sales of $38.2 million, up from $32.8 million a year ago. Gross profit was $26.3 million and the company posted a net loss of $17.5 million, or $0.10 per share. Cash and cash equivalents were $43.1 million, and cash plus short‑term investments totaled $55.5 million as of September 30, 2025.
Product mix showed CINVANTI at $24.0 million, ZYNRELEF $9.3 million, APONVIE $3.0 million, and SUSTOL $1.9 million. Heron refinanced its balance sheet: it amended its Hercules working capital facility to up to $150.0 million and drew $110.8 million; exchanged and extinguished $150.0 million of 2026 convertible notes (including issuing 16.67 million shares for $25.0 million of principal and paying $125.0 million in cash); and issued $35.0 million of 2031 convertible notes. It also raised $27.7 million gross via a private placement of common and Series A preferred stock. The quarter included $11.3 million in loss on debt extinguishment. Management believes its cash, cash equivalents and short‑term investments are sufficient for at least one year.